The fact AHZ could not reach anything like their projected...

The fact AHZ could not reach anything like their projected market shows that trying to go it alone is extremely difficult . A company can have one of the best products in the world but trying to market one or two products by yourself world wide with limited capital is almost impossible . WP obviously had little choice , AHZ had the developed product but no way to get the exposure it needed to advance CardioCel and VascuCel so future ADAPT products including the TAVR would get recognition . Investors need to realise the type of salesmen needed to market these products are not going to be cheap as their Medical knowledge required would justify high wages . Really it would have been great if AHZ could have held both these products as ultimately they would have a range of ADAPT products which could justify a large sales team world wide Unfortunately it wasn’t to be but IMO WP has done a great job saving this company from almost certain bankruptcy . As I stated in previous posts IMO the vaccine section is what ultimately attracted investors but ultimately nearly lead to the company’s downfall . IMO AVR is on track to show investors the returns they assumed they would receive back in the early days of AHZ . Vaccines are always very risky and there was way to much hype generated by Frazers previous success . GLTATH